With Kevzara in COVID-19 testing, Sanofi and Regeneron won't divvy up their rights

As part of CEO Paul Hudson's grand vision at Sanofi, the French drugmaker announced late last year a restructuring of its long-standing antibody partnership with Regeneron.

But one of those partnered drugs, IL-6 inhibitor Kevzara, is now in the spotlight as a possible coronavirus treatment––and at least for now, that partnership will stand.